Curr Opin Immunol. 2025 Jun 4;95:102579. doi: 10.1016/j.coi.2025.102579. Online ahead of print.
ABSTRACT
PURPOSE OF THE REVIEW: To provide an overview of animal models and mechanisms of autoimmune encephalitides associated with autoantibodies against neuronal surface antigens.
PRINCIPAL FINDINGS: Currently, 18 encephalitides are known to be mediated by cell-surface autoantibodies, with 16 targeting neuronal proteins or receptors. These diseases, which can affect patients of all ages, are severe but usually respond to immunotherapy. They also serve as valuable models for studying how immune disruptions of neuronal proteins impair memory, behavior, cognition, or lead to psychosis, seizures, or abnormal movements. The process of modeling these diseases involves three steps: (1) demonstrating that patients’ cerebrospinal fluid (CSF) or serum alters the structure or function of the target antigen; (2) confirming that animal transfer of patient-derived CSF, serum IgG, or monoclonal antibodies replicates the molecular effects and disease symptoms; and (3) developing active immunization-based animal models. While passive transfer models are crucial for demonstrating the pathogenicity of patients’ autoantibodies, they have limitations in fully elucidating the neuro-immunobiology of these diseases (e.g. contribution of T-cells, microglia, native immunity, deep cervical lymph nodes). Additionally, these models fall short in evaluating the long-term clinical course and immunological therapies. Active immunization models, currently available only for anti-NMDAR encephalitis, overcome these limitations, capturing the acute and chronic disease course, introducing novel neuroimmunological paradigms, and enabling the assessment of treatment strategies beyond initial immunotherapy.
CONCLUSIONS: Although animal models are inherently imperfect, current models of autoimmune encephalitides offer valuable neurobiological and immunological insights, facilitating the translation of experimental findings into clinical advancements.
PMID:40472632 | DOI:10.1016/j.coi.2025.102579